Clinical Trials in Tennessee

Showing 3301-3320 of 9,675 trials

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

NCT03451162

This first-in-human, Phase 1, open-label, multicenter, dose-escalation study will evaluate the safety, tolerability, and PK of DHES0815A as a single agent in participants with advanced and/or metastatic HER2-positive breast cancer for whom established treatment has proven ineffective or intolerable or is unavailable. The study may include a dose-expansion cohort (based on an ongoing assessment of the totality of data obtained in this study) to further assess safety, tolerability, PK, and preliminary anti-tumor activity.

Breast Cancer

Genentech, Inc.14 participantsStarted Apr 2018

New Haven, Connecticut, United States • Boston, Massachusetts, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 1/229 miles

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

NCT01712217

The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer(NSCLC)

Astex Pharmaceuticals, Inc.220 participantsStarted Oct 2012

Scottsdale, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +62 more locations

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Find Trials by Condition in Tennessee

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer

Beige Fat, Energy, and the Natriuretic Peptide System

ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

The clonoSEQ® Watch Registry

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

HAART Annuloplasty Device Valve Repair Registry

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Hypertrophic Cardiomyopathy Federated Learning Implementation Platform

Comparative Effectiveness of FITs With Colonoscopy

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

Training for Health Professionals In Tanzania